Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide is associated with improved clinical outcomes in HLA-mismatched unrelated donor hematopoietic cell transplantation
    Meeting Abstract

    Jimenez, A. M.; Perales, M. A.; Devlin, S. M.; Lekakis, L. J.; Sauter, C. S.; Pereira, D.; Beitinjaneh, A.; Brown, S.; Wang, T.; Ponce, D. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs of patients with relapsed/refractory follicular lymphoma receiving 3 or more lines of therapy
    Meeting Abstract

    Matasar, M. J.; Shapouri, S.; Ta, J. T.; To, T. M.; Wu, M.; Wang, R.
    Blood (2021)

    Fulltext@MSK | Save
  • Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (Measurable) residual disease (MRD)
    Meeting Abstract

    Koffman, B.; Stewart, C.; Avruch, L.; Bailey, N.; Brumble, R.; Byrd, J. C.; Danilov, A. V.; Davids, M. S.; Furman, R.; Jain, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Practice gaps and barriers in optimal care among healthcare providers treating patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): Results of a two-phase qualitative/quantitative study
    Meeting Abstract

    Becker, M. N.; Howson, A.; Quill, T. A.; Daver, N.; Stein, E. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical experience in the randomized phase 3 Sierra Trial: Anti-CD45 iodine ((131)I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed/refractory AML not responding to targeted therapies
    Meeting Abstract

    Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Koshy, N. V.; Stiff, P.; Abboud, C. Sr; Tomlinson, B.; Abhyankar, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical manufacture of FT819: Use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy
    Meeting Abstract

    Yuan, X.; Clarke, R.; Lai, Y. S.; Chang, C. W.; Yang, B. H.; Hsia, G.; Abujarour, R.; Lee, T.; van der Stegen, S.; Shaked, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • SRSF2-P95H delays myelofibrosis development through altered JAK/STAT signaling in JAK2(V617F) megakaryocytes
    Meeting Abstract

    Willekens, C.; Laplane, L.; Dagher, T.; Benlabiod, C.; Lacout, C.; Rameau, P.; Catelain, C.; Alfaro, A.; Edmond, V.; Signolle, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save